Macrogenics Inc Has Bullish Trade, Bb Biotech Ag Bought Stake!

February 15, 2018 - By Linda Rogers

 Macrogenics Inc Has Bullish Trade, Bb Biotech Ag Bought Stake!

Investors sentiment decreased to 1.58 in Q3 2017. Its down 0.15, from 1.73 in 2017Q2. It worsened, as 7 investors sold MacroGenics, Inc. shares while 26 reduced holdings. 11 funds opened positions while 41 raised stakes. 27.72 million shares or 0.96% more from 27.45 million shares in 2017Q2 were reported.

Dafna Cap Management Limited Liability Company invested 1.77% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Sphera Funds Management Ltd invested in 208,700 shares. 8 are held by Pnc Services Gru. Rock Springs Mgmt Lp invested 0.19% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Bank & Trust Of America Corporation De stated it has 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). 200,000 are held by Artal Group. 358,161 were accumulated by Emerald Mutual Fund Advisers. Goldman Sachs Grp Incorporated Incorporated has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Dimensional Fund Advsr L P holds 283,517 shares. 1.00M are owned by State Street. Point72 Asia (Hong Kong) holds 0% in MacroGenics, Inc. (NASDAQ:MGNX) or 87 shares. Jennison Assocs Limited Liability Company invested in 0% or 175,225 shares. Principal Fincl Gp Inc reported 114,125 shares stake. Evercore Wealth Mgmt Ltd Liability reported 17,543 shares. Fmr Limited Liability Co holds 4.40 million shares or 0.01% of its portfolio.

Since October 25, 2017, it had 0 insider purchases, and 3 insider sales for $367,500 activity. Wigginton Jon Marc sold $200,000 worth of stock or 10,000 shares.

The New Bb Biotech Ag Holding in Macrogenics Inc

Bb Biotech Ag reported SC 13G/A form with the SEC for Macrogenics Inc. Access it here: 000119312518045515. As reported by Bb Biotech Ag, the filler owns 7.1% or 2,600,412 shares of the Health Care–company.

Macrogenics Inc stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Bb Biotech Ag’s positive view for Macrogenics Inc.

Macrogenics Inc Institutional Sentiment

Filings show 120 investors own Macrogenics Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 4482167. 26047344 were owned by these investors. 19 funds opened new Macrogenics Inc stakes, 59 increased positions. There were 23 that closed positions and 23 reduced them.

Eventide Asset Management Llc is an investor bullish on Macrogenics Inc, owning 709600 shares as of Q3 2015 for 0.88% of its portfolio. Muhlenkamp & Co Inc owns 66500 shares or 0.42% of its portfolio. NY Tiger Management Llc have 1.15% of its portfolio for 403275 shares. Further, Spark Investment Management Llc reported stake worth 0.60% of its portfolio. The MA Mpm Asset Management Llc owns 3168 shares. Macrogenics Inc is 0.01% of its portfolio.

Business Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company’s product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

SEC Form 13G.

Analysts await MacroGenics, Inc. (NASDAQ:MGNX) to report earnings on February, 27. They expect $2.58 earnings per share, up 358.00 % or $3.58 from last year’s $-1 per share. MGNX’s profit will be $95.00 million for 2.30 P/E if the $2.58 EPS becomes a reality. After $-1.28 actual earnings per share reported by MacroGenics, Inc. for the previous quarter, Wall Street now forecasts -301.56 % EPS growth.

The stock decreased 0.29% or $0.07 during the last trading session, reaching $23.78. About 96,294 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has declined 9.76% since February 15, 2017 and is downtrending. It has underperformed by 26.46% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $875.64 million. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 10 analysts covering MacroGenics (NASDAQ:MGNX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. MacroGenics has $56 highest and $20 lowest target. $28.29’s average target is 18.97% above currents $23.78 stock price. MacroGenics had 22 analyst reports since August 6, 2015 according to SRatingsIntel. Citigroup upgraded the stock to “Buy” rating in Monday, October 19 report. The stock has “Buy” rating by Stifel Nicolaus on Thursday, August 6. The rating was downgraded by Zacks on Monday, August 10 to “Buy”. Morgan Stanley maintained it with “Equal-Weight” rating and $21 target in Monday, August 7 report. As per Tuesday, January 23, the company rating was maintained by SunTrust. The company was maintained on Friday, September 1 by SunTrust. Leerink Swann maintained the stock with “Buy” rating in Wednesday, October 25 report. On Monday, September 11 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Buy” rating given on Thursday, February 18 by Janney Capital. The stock has “Neutral” rating by Citigroup on Friday, November 10.

More news for MacroGenics, Inc. (NASDAQ:MGNX) were recently published by: Globenewswire.com, which released: “Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented …” on January 18, 2018. Globenewswire.com‘s article titled: “MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial …” and published on February 14, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.